市場調查報告書

特發性肺纖維化(IPF):開發平台考察(2018年)

Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2020

出版商 DelveInsight Business Research LLP 商品編碼 703500
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
特發性肺纖維化(IPF):開發平台考察(2018年) Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2020
出版日期: 2020年01月01日內容資訊: 英文 60 Pages
簡介

本報告提供突發性肺纖維症(IPF)治療藥的相關調查,市場概要,各臨床實驗階段的產品概要,已上市、開發暫停中的產品的評估,市場成長預測,企業簡介等資訊總括性彙整。

目錄

第1章 報告概要

第2章 摘要整理

第3章 特發性肺纖維化(IPF):概要

  • 原因
  • 徵兆與症狀
  • 診斷
  • 治療
  • 流行病學

第4章 開發平台治療藥

第5章 比較分析

第6章 臨床實驗後期階段的產品(第三階段實驗)

  • 比較分析
  • 血栓調節蛋白α:旭化成製藥
    • 產品說明
    • 研究開發
    • 產品開發

第7章 臨床實驗中期階段的產品(第二階段實驗)

  • 比較分析
  • GLPG1690:Galapagos
    • 產品說明
    • 研究開發
    • 產品開發
  • PBI4050:ProMetic
  • Pamrevlumab:FibroGen
    • 產品開發
  • BG-00011:Biogen

第8章 臨床實驗前期階段的產品(第一階段實驗)

  • 比較分析
  • HEC585:HEC Pharm
    • 產品說明
    • 研究開發
    • 產品開發
  • AEOL 10150:Aeolus Pharmaceuticals
    • 產品開發
  • C21:Vicore Pharma

第9章 治療藥的評估:已上市產品

  • 各階段、產品
  • 各核准途徑
  • 各階段、核准途徑
  • 各分子類型
  • 各階段、分子類型

第10章 開發暫停中的產品

  • 比較分析

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIPI0146

Idiopathic Pulmonary Fibrosis Overview

"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2020" Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Idiopathic Pulmonary Fibrosis Market. A Detailed Picture Of The Idiopathic Pulmonary Fibrosis Pipeline Landscape Is Provided, Which Includes The Disease Overview And Idiopathic Pulmonary Fibrosis Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Idiopathic Pulmonary Fibrosis Commercial Assessment And Clinical Assessment Of The Idiopathic Pulmonary Fibrosis Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Idiopathic Pulmonary Fibrosis Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

Idiopathic Pulmonary Fibrosis Of Pipeline Development Activities

The Report Provides Insights Into:

  • All Of The Companies That Are Developing Therapies For The Treatment Of Idiopathic Pulmonary Fibrosis With Aggregate Therapies Developed By Each Company For The Same.
  • Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Idiopathic Pulmonary Fibrosis Treatment.
  • Idiopathic Pulmonary Fibrosis Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.
  • Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
  • Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Idiopathic Pulmonary Fibrosis Market.
  • The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Idiopathic Pulmonary Fibrosis Analytical Perspective By DelveInsight

  • In-Depth Idiopathic Pulmonary Fibrosis Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

  • Idiopathic Pulmonary Fibrosis Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

Scope Of The Report

  • The Idiopathic Pulmonary Fibrosis Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Idiopathic Pulmonary Fibrosis Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
  • It Comprises Of Detailed Profiles Of Idiopathic Pulmonary Fibrosis Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details
  • Detailed Idiopathic Pulmonary Fibrosis Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.
  • Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Idiopathic Pulmonary Fibrosis.

Report Highlights

  • A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Idiopathic Pulmonary Fibrosis.
  • In The Coming Years, The Idiopathic Pulmonary Fibrosis Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.
  • The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Idiopathic Pulmonary Fibrosis R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.
  • A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Idiopathic Pulmonary Fibrosis Treatment Market. Several Potential Therapies For Idiopathic Pulmonary Fibrosis Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Idiopathic Pulmonary Fibrosis Market Size In The Coming Years.
  • Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Idiopathic Pulmonary Fibrosis ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

Key Questions

  • What Are The Current Options For Idiopathic Pulmonary Fibrosis Treatment?
  • How Many Companies Are Developing Therapies For The Treatment Of Idiopathic Pulmonary Fibrosis?
  • What Are The Principal Therapies Developed By These Companies In The Industry?
  • How Many Therapies Are Developed By Each Company For The Treatment Of Idiopathic Pulmonary Fibrosis?
  • How Many Idiopathic Pulmonary Fibrosis Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Idiopathic Pulmonary Fibrosis?
  • Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
  • What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Idiopathic Pulmonary Fibrosis Market?
  • Which Are The Dormant And Discontinued Products And The Reasons For The Same?
  • What Is The Unmet Need For Current Therapies For The Treatment Of Idiopathic Pulmonary Fibrosis?
  • What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Idiopathic Pulmonary Fibrosis Therapies?
  • What Are The Clinical Studies Going On For Idiopathic Pulmonary Fibrosis And Their Status?
  • What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
  • What Are The Key Designations That Have Been Granted For The Emerging Therapies For Idiopathic Pulmonary Fibrosis?
  • How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Idiopathic Pulmonary Fibrosis?

Table of Contents

1. Report Introduction

2. Idiopathic Pulmonary Fibrosis

  • 2.1. Overview
  • 2.2. History
  • 2.3. Idiopathic Pulmonary Fibrosis Symptoms
  • 2.4. Causes

2.5.Pathophysiology

  • 2.6. Idiopathic Pulmonary Fibrosis Diagnosis
    • 2.6.1. Diagnostic Guidelines

3. Idiopathic Pulmonary Fibrosis Current Treatment Patterns

  • 3.1. Idiopathic Pulmonary Fibrosis Treatment Guidelines

4. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective

  • 4.1. In-depth Commercial Assessment
    • 4.1.1. Idiopathic Pulmonary Fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends
      • 4.1.1.1. Assessment Summary
    • 4.1.2. Idiopathic Pulmonary Fibrosis Collaboration Deals
      • 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
      • 4.1.2.3. Idiopathic Pulmonary Fibrosis Acquisition Analysis

5. Therapeutic Assessment

  • 5.1. Clinical Assessment of Pipeline Drugs
    • 5.1.1. Assessment by Phase of Development
    • 5.1.2. Assessment by Product Type (Mono / Combination)
      • 5.1.2.1. Assessment by Stage and Product Type
    • 5.1.3. Assessment by Route of Administration
      • 5.1.3.1. Assessment by Stage and Route of Administration
    • 5.1.4. Assessment by Molecule Type
      • 5.1.4.1. Assessment by Stage and Molecule Type
    • 5.1.5. Assessment by MOA
      • 5.1.5.1. Assessment by Stage and MOA
    • 5.1.6. Assessment by Target
      • 5.1.6.1. Assessment by Stage and Target

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase-III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Idiopathic Pulmonary Fibrosis Discontinued Products

13. Idiopathic Pulmonary Fibrosis Product Profiles

  • 13.1. Drug Name: Company
    • 13.1.1. Product Description
      • 13.1.1.1. Product Overview
      • 13.1.1.2. Mechanism of action
    • 13.1.2. Research and Development
      • 13.1.2.1. Clinical Studies
    • 13.1.3. Product Development Activities
      • 13.1.3.1. Collaboration
      • 13.1.3.2. Agreements
      • 13.1.3.3. Acquisition
      • 13.1.3.4. Patent Detail
    • 13.1.4. Tabulated Product Summary
      • 13.1.4.1. General Description Table

Detailed information in the report?

14. Idiopathic Pulmonary Fibrosis Key Companies

15. Idiopathic Pulmonary Fibrosis Key Products

16. Dormant and Discontinued Products

  • 16.1. Dormant Products
    • 16.1.1. Reasons for being dormant
  • 16.2. Discontinued Products
    • 16.2.1. Reasons for the discontinuation

17. Idiopathic Pulmonary Fibrosis Unmet Needs

18. Idiopathic Pulmonary Fibrosis Future Perspectives

19. Idiopathic Pulmonary Fibrosis Analyst Review

20. Appendix

21. Report Methodology

  • 21.1. Secondary Research
  • 21.2. Expert Panel Validation

List of Tables

  • Table 1: Idiopathic Pulmonary Fibrosis Diagnostic Guidelines
  • Table 2: Idiopathic Pulmonary Fibrosis Treatment Guidelines
  • Table 3: Assessment Summary
  • Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Table 5: Idiopathic Pulmonary Fibrosis Acquisition Analysis
  • Table 6: Assessment by Phase of Development
  • Table 7: Assessment by Product Type (Mono / Combination)
  • Table 8: Assessment by Stage and Product Type
  • Table 9: Assessment by Route of Administration
  • Table 10: Assessment by Stage and Route of Administration
  • Table 11: Assessment by Molecule Type
  • Table 12: Assessment by Stage and Molecule Type
  • Table 13: Assessment by MOA
  • Table 14: Assessment by Stage and MOA
  • Table 15: Assessment by Target
  • Table 16: Assessment by Stage and Target
  • Table 17: Idiopathic Pulmonary Fibrosis Late Stage Products (Phase-III)
  • Table 18: Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase-II)
  • Table 19: Idiopathic Pulmonary Fibrosis Early Stage Products (Phase-I)
  • Table 20: Pre-clinical and Discovery Stage Products
  • Table 21: Inactive Products
  • Table 22: Dormant Products
  • Table 23: Discontinued Products

List of Figures

  • Figure 1: Disease Overview
  • Figure 2: History
  • Figure 3: Symptoms
  • Figure 4: Causes
  • Figure 5: Pathophysiology
  • Figure 6: Diagnostic Guidelines
  • Figure 7: Treatment Guidelines
  • Figure 8: Idiopathic Pulmonary Fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends
  • Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
  • Figure 10: Idiopathic Pulmonary Fibrosis Acquisition Analysis
  • Figure 11: Assessment by Phase of Development
  • Figure 12: Assessment by Product Type (Mono / Combination)
  • Figure 13: Assessment by Stage and Product Type
  • Figure 14: Assessment by Route of Administration
  • Figure 15: Assessment by Stage and Route of Administration
  • Figure 16: Assessment by Molecule Type
  • Figure 17: Assessment by Stage and Molecule Type
  • Figure 18: Assessment by MOA
  • Figure 19: Assessment by Stage and MOA
  • Figure 20: Late Stage Products (Phase-III)
  • Figure 21: Mid Stage Products (Phase-II)
  • Figure 22: Early Stage Products (Phase-I)
  • Figure 23: Pre-clinical and Discovery Stage Products
  • Figure 24: Inactive Products
  • Figure 25: Dormant Products
  • Figure 26: Discontinued Products
  • Figure 27: Unmet Needs